Navigation Links
Boehringer Ingelheim Announces Agreement to Study Real-World Use of Oral Anticoagulants
Date:8/15/2013

RIDGEFIELD, Conn., Aug. 15, 2013 /PRNewswire/ -- Boehringer Ingelheim, a research-based, global pharmaceutical company, today announced a multi-year agreement with Brigham and Women's Hospital, an internationally recognized teaching affiliate of Harvard Medical School known for its excellence in patient care, medical research and training of outstanding young health professionals. Under this agreement, Brigham and Women's Hospital will conduct a long-term study program to assess comparative effectiveness and safety, as well as prescribing patterns, of oral anticoagulants, including PRADAXA, for the reduction of stroke risk in U.S. patients with non-valvular atrial fibrillation (NVAF).

The objective of this long-term study program is to better understand the real-world safety and effectiveness of warfarin and newer oral anticoagulants, including PRADAXA. Brigham and Women's Hospital will analyze claims data from UnitedHealth Group's research database, which is managed by one of the largest health care companies in the United States, serving more than 80 million individuals worldwide.

"It is our hope that the results of this study program will improve awareness that stroke risk related to NVAF is a growing public health issue and increase understanding of real-world experiences with new oral anticoagulants on the market to reduce stroke risk," said Sebastian Schneeweiss, vice chief, Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, and Professor of Medicine and Epidemiology, Harvard Medical School. "This research will allow us to produce additional data over several years that will help the medical community and patients understand the risks and benefits of anticoagulants used to reduce the risk of stroke associated with non-valvular atrial fibrillation."

This study program demonstrates the commitment of Boehringer Ingelheim
'/>"/>

SOURCE Boehringer Ingelheim
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Boehringer Ingelheim Renews and Expands License to NextBio Research Platform
2. Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company Statement on the ADA Request for Independent Review of Incretin-Based Therapies
3. Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference
4. Boehringer Ingelheim Presents Progression-Free Survival Data for Investigational Afatinib and Nintedanib in Advanced NSCLC
5. ASCO 2013: Boehringer Ingelheim to Present Data Across Multiple Cancers, Including Different Treatment Settings for Advanced NSCLC
6. Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company launch educational campaign about emerging science in type 2 diabetes
7. Boehringer Ingelheim to Announce Pivotal Phase 3 Hepatitis C Data at the International Liver Congress
8. European Medicines Agency accepts marketing authorization application for Boehringer Ingelheim and Eli Lilly and Companys empagliflozin*, an investigational type 2 diabetes treatment
9. Boehringer Ingelheim and Eli Lilly and Company submit new drug application to FDA for empagliflozin, an investigational type 2 diabetes treatment
10. Boehringer Ingelheim Announces Interim Results Evaluating Virologic Response Rates in HCV/HIV Co-Infected Patients Treated with Faldaprevir
11. Boehringer Ingelheim Cares Foundation Launches Online Giving Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... BERWYN, Pa. , July 25, 2014  AMETEK, ... appointment of Kurtis L. Goos as Vice ... Engineered Materials, Interconnects and Packaging (EMIP) Division. ... has extensive general management and business development experience, especially ... to make important contributions to the continued growth and ...
(Date:7/25/2014)... NORTH CHICAGO, Ill., July 25, 2014 ... PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION ... RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION AbbVie (NYSE: ... quarter ended June 30, 2014. "This was ... and earnings per share above our original guidance and announced ...
(Date:7/24/2014)... , July 24, 2014   AcelRx Pharmaceuticals, Inc. ... focused on the development and commercialization of innovative therapies ... confirmed the PDUFA date for Zalviso remains July 27, ... rumor circulated online stating the Food and Drug Administration ... there has been no notification to the company from ...
Breaking Medicine Technology:AMETEK Names Kurtis L. Goos, Vice President & General Manager, Engineered Medical Components 2AbbVie Reports Second-Quarter 2014 Financial Results 2AbbVie Reports Second-Quarter 2014 Financial Results 3AbbVie Reports Second-Quarter 2014 Financial Results 4AbbVie Reports Second-Quarter 2014 Financial Results 5AbbVie Reports Second-Quarter 2014 Financial Results 6AbbVie Reports Second-Quarter 2014 Financial Results 7AbbVie Reports Second-Quarter 2014 Financial Results 8AbbVie Reports Second-Quarter 2014 Financial Results 9AbbVie Reports Second-Quarter 2014 Financial Results 10AbbVie Reports Second-Quarter 2014 Financial Results 11AbbVie Reports Second-Quarter 2014 Financial Results 12AbbVie Reports Second-Quarter 2014 Financial Results 13AbbVie Reports Second-Quarter 2014 Financial Results 14AbbVie Reports Second-Quarter 2014 Financial Results 15AbbVie Reports Second-Quarter 2014 Financial Results 16AbbVie Reports Second-Quarter 2014 Financial Results 17AbbVie Reports Second-Quarter 2014 Financial Results 18AbbVie Reports Second-Quarter 2014 Financial Results 19AbbVie Reports Second-Quarter 2014 Financial Results 20AbbVie Reports Second-Quarter 2014 Financial Results 21AbbVie Reports Second-Quarter 2014 Financial Results 22AbbVie Reports Second-Quarter 2014 Financial Results 23AbbVie Reports Second-Quarter 2014 Financial Results 24AbbVie Reports Second-Quarter 2014 Financial Results 25AbbVie Reports Second-Quarter 2014 Financial Results 26AbbVie Reports Second-Quarter 2014 Financial Results 27AbbVie Reports Second-Quarter 2014 Financial Results 28AbbVie Reports Second-Quarter 2014 Financial Results 29AbbVie Reports Second-Quarter 2014 Financial Results 30AbbVie Reports Second-Quarter 2014 Financial Results 31AbbVie Reports Second-Quarter 2014 Financial Results 32AbbVie Reports Second-Quarter 2014 Financial Results 33AbbVie Reports Second-Quarter 2014 Financial Results 34AbbVie Reports Second-Quarter 2014 Financial Results 35
... 5, 2011 meridianEMR, the market leader in EHR ... Somerville, New Jersey was the first meridianEMR customer to ... Centers for Medicare and Medicaid Services (CMS). On July ... $54,000 for three physicians via direct deposit. The group ...
... Biotech Ltd. (Nasdaq: SVA ), a leading ... of Jacob Chik Keung Ho, its Chief Financial Officer, for ... a new Chief Financial Officer to replace Mr. Ho, who ... 2011.  Ms. Nan Wang, Vice President of Sinovac, has been ...
Cached Medicine Technology:meridianEMR® Customers Start Receiving Meaningful Use Incentive Payments 2meridianEMR® Customers Start Receiving Meaningful Use Incentive Payments 3Sinovac Announces Management Changes 2Sinovac Announces Management Changes 3
(Date:7/25/2014)... Garth Brooks Chicago tickets go on sale Friday, ... Garth Brooks was one of the leaders on the country ... 1989. Since "Much Too Young (To Feel This Damn Old)" was ... Okl. native and in the years that he has been away ... stage and in the recording studio. Between 2001 and 2009, fans ...
(Date:7/25/2014)... 25, 2014 -- The Elizabeth Glaser Pediatric AIDS ... the Medicines Patent Pool (MPP) and Gilead Sciences, ... (TAF), a promising new HIV medication. The agreement ... (AIDS 2014) in Melbourne, Australia. , While ... early data suggests it could be a key ...
(Date:7/25/2014)... A report released by the Juvenile Diabetes ... 2013 (July 1, 2012- June 30, 2013). , Outside of ... is the largest single funder of type 1 diabetes research ... with most of the top research centers. There is ... 1 diabetes in the near future. , Since the 2008 ...
(Date:7/25/2014)... Mateo, CA (PRWEB) July 25, 2014 ... an upcoming episode of Innovations with Ed Begley Jr, ... and show times TBA. , For more than four ... the Bay Area community through its residential alcohol and ... will educate on Project Ninety's humble idea and how ...
(Date:7/25/2014)... 2014 Stwd.co.uk, one of the leading ... of cheap evening dress for women. In ... big promotion for these items. They are available at ... last until August 30. , “We are pleased to ... outfits, we have a large number of stylish special ...
Breaking Medicine News(10 mins):Health News:Garth Brooks Chicago Tickets for Performance at Allstate Arena in Rosemont Go On Sale July 25th 2Health News:Garth Brooks Chicago Tickets for Performance at Allstate Arena in Rosemont Go On Sale July 25th 3Health News:Report: JDRF 2013 Annual Research Spending Down by $50 million 2Health News:Project Ninety to be Featured on Innovations with Ed Begley, Jr. 2Health News:Project Ninety to be Featured on Innovations with Ed Begley, Jr. 3Health News:Famous Supplier Stwd.co.uk Announces Its New Selection of Evening Dresses for Women 2
... The number of airline mishaps attributed to pilot error ... analysis conducted by researchers at the Johns Hopkins Bloomberg ... airline mishaps remained stable during that time, the proportion ... rate of mishaps related to a pilots poor decision-making ...
... New Advice for Doctors About Low-Fat, Low-Carb Restricted ... 28 The American,Diabetes Association (ADA) today issued ... providers treat people with diabetes,using the most current ... occurs in the Medical Nutrition Therapy,section dealing with ...
... deprive them of rest needed for healing, study says ... patterns of intensive care unit (ICU) patients are so ... restorative phases of sleep that help promote healing, says ... Southwestern Medical Center at Dallas. , The study ...
... Eclipsys Corporation(R),(Nasdaq: ECLP ), The Outcomes ... 2008 JPMorgan Healthcare Conference taking place from,January 7th ... http://www.newscom.com/cgi-bin/prnh/20050209/FLW006LOGO ), Eclipsys executives will ... 3:00 p.m. Pacific time. To access the live ...
... The National Drug,Intelligence Center (NDIC), a ... nation,s principal center for strategic drug intelligence, ... This strategic,assessment presents an analysis of key ... and abuse in the,United States. The assessment ...
... SAN FRANCISCO, Dec. 27 OneMedPlace will hold its ... the Sir Francis Drake,Hotel in Union Square., This ... cap public,companies and early stage venture backed companies to ... both public and private, will present at,the conference and ...
Cached Medicine News:Health News:Pilot error declines as factor in airline mishaps 2Health News:ADA Issues New Clinical Practice Recommendations 2Health News:ADA Issues New Clinical Practice Recommendations 3Health News:ICU Patients Not Getting Enough Sleep 2Health News:Eclipsys to Present at JPMorgan Healthcare Conference 2Health News:Eclipsys to Present at JPMorgan Healthcare Conference 3Health News:National Drug Intelligence Center Releases 2008 National Methamphetamine Threat Assessment 2Health News:OneMedPlace Emerging Healthcare Technologies Finance Forum Jan 7, 8th 2
... non-adhesive sealing method maintains the ... (HALS) procedures, allowing the surgeon ... throughout. Because HALS requires incisions ... patients experience less trauma compared ...
... series offers a range of standard, ... design delivers therapy to meet the ... results in commercial and clinical effectiveness ... in the SleepStyle 200 series is ...
... The SleepStyle 200 series offers ... integrated CPAP models. The design delivers ... patients. Performance features promote results in ... care. The strongest differentiator in the ...
... series offers a range of standard, ... design delivers therapy to meet the ... results in commercial and clinical effectiveness ... in the SleepStyle 200 series is ...
Medicine Products: